BOchum heaRt failurE in Aortic Stenosis study - Prospective diagnostic study to investigate the hemodynamic and cell biological basis of an irreversible left ventricular failure in severe aortic stenosis

BOchum heaRt failurE in Aortic Stenosis study - Prospective diagnostic study to investigate the hemodynamic and cell biological basis of an irreversible left ventricular failure in severe aortic stenosis - BOREAS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00005623

Enrollment

Registered

2014-01-09

Start date

2014-09-17

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I35.0 I42.8

Interventions

Group 1: Hemodynamic, histopathological and cell biological analyzes in patients with severe aortic stenosis (valve area 40 mmHg. Group 2: Hemodynamic, histopathological and cell biological analyzes

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria study group aortic stenosis and left ventricular failure - Severe aortic stenosis ( valve area 1 years - Consent to participate in the study Inclusion criteria control group aortic stenosis without left ventricular failure - Severe aortic stenosis ( valve area 1 years - Consent to participate in the study

Exclusion criteria

Exclusion criteria: - Active endocarditis - Previous myocardial infarction - Previous heart surgery - Concurrent serious stenosis or insufficiency of the mitral valve - Concurrent serious insufficiency of the aortic valve - Pregnancy, lactation

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the normalization of left ventricular ejection fraction of = 50% three months after aortic valve replacement.	—

Secondary

Measure	Time frame
Comparison of reversible and irreversible left ventricular failure: - N2BA/N2B-Isoform titin expression ratio and phosphorylation - Active contraction of the cardiomyocytes - The degree of myocardial fibrosis - All-cause mortality (one-year) - Cardiovascular mortality (one-year) - Hospitalization for heart failure (within the first year after aortic valve replacement)	—

Countries

Germany

Contacts

Public ContactMichael Gotzmann

Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil GmbH

Michael.Gotzmann@ruhr-uni-bochum.de0234 302 3229

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026